Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PXD101 in Advanced Multiple Myeloma
NCT00131261Phase 2Completed
- Sponsor
- Valerio Therapeutics
- Start
- Jan 2005
- Primary completion
- Jan 2007
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of belinostat in multiple myeloma (MM), sponsored by Valerio Therapeutics. Primary endpoints: Objective Response Rate and Safety and Tolerability. Started Jan 2005; status: completed.
02
Drugs
belinostat
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00131261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00131261.